Company Description

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurogenerative diseases.

Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.

The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

CervoMed Inc.

Country	United States
Founded	2001
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Dr. John J. Alam M.D.

Contact Details

Address: 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 United States
Phone	(617) 744-4400
Website	cervomed.com

Stock Details

Ticker Symbol	CRVO
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001053691
Employer ID	30-0645032
SIC Code	2834

Key Executives

Name	Position
Dr. John J. Alam M.D.	Co-Founder, Chief Executive Officer, President and Director
Dr. Sylvie L. Gregoire Pharm.D.	Co-Founder and Director
William Robert Elder J.D.	General Counsel, Corporate Secretary and Acting Principal Financial Officer
Dr. Robert J. Cobuzzi Jr., Ph.D.	Chief Operating Officer and Director
Dr. John William Tanner Ph.D.	Chief Financial Officer (Leave of Absence)
Kelly Blackburn M.H.A.	Senior Vice President of Clinical Development

Latest SEC Filings

Date	Type	Title
Apr 11, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals
Apr 5, 2024	8-K	Current Report
Apr 4, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report
Mar 6, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Mar 5, 2024	8-K	Current Report
Feb 28, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Feb 28, 2024	8-K	Current Report

View All SEC Filings